• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BioAtla Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/6/25 4:01:37 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCAB alert in real time by email
    8-K
    0001826892falseBioAtla, Inc.00018268922025-05-062025-05-06

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 06, 2025

     

     

    BIOATLA, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-39787

    85-1922320

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    11085 Torreyana Road

     

    San Diego, California

     

    92121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 858 558-0708

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.0001 par value per share

     

    BCAB

     

    Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 6, 2025, BioAtla, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025 and provided an update on its ongoing clinical programs. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Item 2.02 of this Current Report on Form 8-K (“Current Report”), including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information set forth in Item 2.02 of this Current Report, including Exhibit 99.1 attached hereto, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

     

     

    Exhibit

    Description

    99.1

    Press Release dated May 6, 2025

    104

    Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    BioAtla Inc.

     

     

     

     

    Date:

    May 6, 2025

    By:

    /s/ Richard A. Waldron

     

     

     

    Richard A. Waldron
    Chief Financial Officer

     


    Get the next $BCAB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BCAB

    DatePrice TargetRatingAnalyst
    11/13/2024Buy → Neutral
    H.C. Wainwright
    9/15/2022$17.00Mkt Outperform
    JMP Securities
    5/5/2022$35.00 → $5.00Outperform → Neutral
    Credit Suisse
    3/21/2022$25.00Buy
    H.C. Wainwright
    10/15/2021$68.00Buy
    BTIG Research
    6/28/2021$75.00Buy
    ROTH Capital
    More analyst ratings

    $BCAB
    SEC Filings

    See more
    • BioAtla Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - BioAtla, Inc. (0001826892) (Filer)

      6/20/25 4:06:53 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by BioAtla Inc.

      SCHEDULE 13G/A - BioAtla, Inc. (0001826892) (Subject)

      5/20/25 2:26:28 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - BioAtla, Inc. (0001826892) (Filer)

      5/16/25 5:05:56 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

      Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients Dose escalation now continuing at 1.2 mg weekly by subcutaneous flat dosing SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB) (the "Company" or "BioAtla"), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today presented first-in-human data in a poster titled "Preliminary Results from a First-in-Human Phase 1 Study of a Dual-Conditionally Binding CAB-

      7/3/25 8:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

      45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy Marked unmet need exists in 2L+ HPV+ OPSCC patients; standard of care agents (methotrexate, docetaxel, or cetuximab) report an ORR of 3.4% Plan to finalize Phase 3 trial design in 2L+ HPV+ OPSCC with the U.S. Food and Drug Administration (FDA) SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB) (the "Company"), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced data in a poster titled, "Phase

      6/2/25 8:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

      CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agentsOzuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study continues to demonstrate compelling signals in HPV-positive squamous cell carcinoma of the head and neck (SCCHN) patients; Company utilizing Fas

      5/6/25 4:05:00 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Moran Susan was granted 23,500 shares, increasing direct ownership by 82% to 52,307 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      6/18/25 7:45:08 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Williams Eddie was granted 23,500 shares, increasing direct ownership by 64% to 60,200 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      6/18/25 7:44:33 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Steinman Lawrence was granted 23,500 shares, increasing direct ownership by 43% to 78,459 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      6/18/25 7:44:03 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BioAtla downgraded by H.C. Wainwright

      H.C. Wainwright downgraded BioAtla from Buy to Neutral

      11/13/24 7:31:56 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on BioAtla with a new price target

      JMP Securities initiated coverage of BioAtla with a rating of Mkt Outperform and set a new price target of $17.00

      9/15/22 7:31:28 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla downgraded by Credit Suisse with a new price target

      Credit Suisse downgraded BioAtla from Outperform to Neutral and set a new price target of $5.00 from $35.00 previously

      5/5/22 6:12:47 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mcbrinn Sylvia bought $9,400 worth of shares (4,000 units at $2.35), increasing direct ownership by 26% to 19,125 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      1/19/24 4:21:50 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mcbrinn Sylvia bought $9,320 worth of shares (4,000 units at $2.33), increasing direct ownership by 36% to 15,125 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      12/26/23 7:43:02 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Short Jay M Phd bought $106,910 worth of shares (50,000 units at $2.14), increasing direct ownership by 4% to 1,439,283 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      12/20/23 6:27:44 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Leadership Updates

    Live Leadership Updates

    See more
    • BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS

      SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committee of the Board.  Mr. Williams has extensive executive experience in the biopharmaceutical industry and as a member of the board of directors of a biotechnology company in late-stage clinical development. Jay M. Short, Ph.D., Chairman of the Board and Chief Executive Officer, stated, "Eddie's career of demonstrated success and knowledge in growing biopharmaceuti

      12/21/21 9:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Financials

    Live finance-specific insights

    See more
    • BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

      CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agentsOzuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study continues to demonstrate compelling signals in HPV-positive squamous cell carcinoma of the head and neck (SCCHN) patients; Company utilizing Fas

      5/6/25 4:05:00 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

      SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025 and provide business highlights. Conference Call and Webcast Information        Date: Tuesday, May 6, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)Con

      4/29/25 8:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

      CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overall survival (OS) with 66% and 58% of patients with mKRAS NSCLC alive at a landmark one-year and two-years, respectively, which exceeds the reported standard of care Ozuriftamab vedotin (CAB-ROR2-ADC) demonstrated compelling anti-tumor activity in treatment-refractory, metastatic HPV-positive squamous cell carcinoma of the head and neck (SCCHN); a population which is poorly served by EGFR inhibitorsCash balance of $49mm at year-end 2024 with recent cost-redu

      3/27/25 4:05:00 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BioAtla Inc.

      SC 13G/A - BioAtla, Inc. (0001826892) (Subject)

      11/14/24 4:00:05 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

      SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

      10/2/24 4:30:04 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

      SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

      9/6/24 4:59:38 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care